|
Mountain View, CA, September 29, 2003 —SurroMed, Inc. recently published findings in the September 15, 2003
issue of Analytical Chemistry, describing a new approach for biomarker identification. The paper details
their new liquid chromatography-mass spectrometry approach to quantitative profiling of large numbers of proteins
(proteomics) and small molecules (metabolomics) for the purpose of differential expression measurements and discovery
of biomarkers. This technology, which employs liquid chromatography-mass spectrometry (LC-MS), offers drug discovery
researchers an improved method for biomarker discovery from complex biological samples.
The study entitled “Quantification of Proteins and Metabolites by Mass Spectrometry without Isotopic Labeling or
Spiked Standards” was performed by SurroMed’s chemistry department under the direction of corresponding author
Christopher Becker, Ph. D., SurroMed’s director of chemistry. Dr. Becker said, “We found that direct quantification
without isotopic labeling or spiking of matched internal standards offers advantages, such as simple sample processing,
applicability to both proteome and metabolome samples, and less spectral interference. We observed a high degree of
signal versus concentration linearity. This linearity, together with a high degree of reproducibility, satisfies the
fundamental requirements for quantifying differential expression experiments involving unanticipated molecules.”
“This enabling discovery for differential proteomics and metabolomics represents significant progress in the advancement
of our core technologies for the identification of biomarkers, ” said Howard Schulman, Ph. D., vice-president of research
and development. “The results underpin the creative talent of our research teams as they continue to invent new ways to
more efficiently identify biomarkers for our discovery and development programs.”
About SurroMed, Inc. - The Biomarker Company
SurroMed is pioneering biomarker enabled drug discovery and development. The company
focuses on discovering and applying biomarkers to improve the drug discovery and
development process and enable the precise diagnosis and personalized treatment of
disease. SurroMed's research process yields biological markers and information that
enable accelerated, cost-efficient discovery and development of new therapeutic products,
as well as development of diagnostic tests for early disease detection, disease staging,
patient stratification, and guiding and monitoring therapy.
Contacts:
SurroMed, Inc.
August J. Moretti
CFO and General Counsel
(650) 230-1564
email: [email protected]
Noonan/Russo Communications, Inc.
Ian McConnell, Ph.D
Senior Account Executive
(415) 677-4455 ext. 233
email: [email protected]
|
